Page 6 - Michael Strapazon News Today

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZenecas Tezspire™...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZenecas Tezspire™...

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled,...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- The National Osteoporosis Foundation (NOF) today announced a collaboration with Medstar Health in Maryland and Atrium Health in North Carolina...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from real-world data in Asia, Europe, Oceania, and North and South America on the temporal trends...

Amgen today announced results from real-world data in Asia Europe Oceania, and North and South America on the temporal trends in hip fracture incidence, and in post-fracture pharmacological treatment intervention. The study, presented as a late-breaking abstract at the American Society for Bone and Mineral Research 2021 Annual Meeting is titled " Hip Fractures: Initial Report of Trends in Incidence, Treatment, and ...

/PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were...